Evogene Appoints Pharma Veteran to Drive Business Development
Event summary
- Evogene appointed Dr. Olga Nissan as Vice President of Business Development, effective January 1, 2026.
- Dr. Nissan previously served as CEO and Co-Founder of Protica Bio, and held roles at EcoPhage, BiomX, and Teva Pharmaceutical Industries.
- She holds a PhD and postdoctoral research experience from the Weizmann Institute of Science.
- Evogene’s CEO, Ofer Haviv, highlighted Dr. Nissan’s experience in AI-enabled drug discovery and company building.
- The appointment aims to scale Evogene’s small-molecule discovery and optimization offering, powered by its ChemPass AI engine.
The big picture
Evogene’s move to bring in a seasoned executive like Dr. Nissan signals an acceleration of its business development efforts, reflecting the growing interest in AI-driven drug discovery. The company’s focus on small molecule design positions it within a competitive landscape, where speed and efficiency are critical for success. Dr. Nissan’s experience across multiple sectors suggests a deliberate effort to diversify Evogene’s revenue streams and mitigate risk.
What we're watching
- Partnership Impact
- The success of Evogene’s expansion will hinge on Dr. Nissan’s ability to forge and manage strategic partnerships, given the company’s reliance on collaborations for product development.
- ChemPass Adoption
- The rate at which Evogene can integrate ChemPass AI into its workflows and demonstrate tangible results will be a key indicator of the platform’s value proposition.
- Geopolitical Risk
- The ongoing conflict in Israel and its potential escalation could significantly disrupt Evogene’s operations and collaborations, impacting the timeline for Dr. Nissan’s initiatives.
Related topics